| 1 |
34261913 | Norcantharidin counteracts acquired everolimus resistance in renal cell carcinoma by dual inhibition of mammalian target of rapamycin complex 1 and complex 2 pathways in Vitro. | 2022 Jan 1 |
4 |
| 2 |
35136028 | Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer. | 2022 Feb 8 |
1 |
| 3 |
33574130 | Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation. | 2021 May |
1 |
| 4 |
33727259 | Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. | 2021 Jul 15 |
1 |
| 5 |
33785482 | Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). | 2021 Jun 15 |
1 |
| 6 |
33804593 | PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successfully Treated with Everolimus: A Case Report. | 2021 Mar 20 |
1 |
| 7 |
33889306 | High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC. | 2021 Apr 13 |
2 |
| 8 |
33931486 | Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and Number. | 2021 May 15 |
1 |
| 9 |
34045438 | Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS. | 2021 May 28 |
1 |
| 10 |
34224367 | Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. | 2021 Sep |
2 |
| 11 |
34640378 | Complete Purging of Ewing Sarcoma Metastases from Human Ovarian Cortex Tissue Fragments by Inhibiting the mTORC1 Signaling Pathway. | 2021 Sep 24 |
1 |
| 12 |
34648891 | Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. | 2021 Nov 10 |
1 |
| 13 |
34959437 | Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [177Lu]Lu-PP-F11N. | 2021 Dec 15 |
1 |
| 14 |
31463638 | The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma. | 2020 Aug |
2 |
| 15 |
31597506 | Two novel TSC2 mutations in renal epithelioid angiomyolipoma sensitive to everolimus. | 2020 |
1 |
| 16 |
31879363 | Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance. | 2020 Mar |
1 |
| 17 |
32215854 | Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1. | 2020 Jun |
4 |
| 18 |
32252811 | Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. | 2020 Apr 6 |
3 |
| 19 |
32393148 | PKG1α Cysteine-42 Redox State Controls mTORC1 Activation in Pathological Cardiac Hypertrophy. | 2020 Jul 31 |
1 |
| 20 |
32411241 | AdipoRon Affects Cell Cycle Progression and Inhibits Proliferation in Human Osteosarcoma Cells. | 2020 |
1 |
| 21 |
32716476 | The rapamycin analog Everolimus reversibly impairs male germ cell differentiation and fertility in the mouse†. | 2020 Oct 29 |
1 |
| 22 |
32759497 | Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity. | 2020 Aug 6 |
4 |
| 23 |
33079326 | Follicle inhibition at the primordial stage without increasing apoptosis, with a combination of everolimus, verapamil. | 2020 Nov |
1 |
| 24 |
33182575 | Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. | 2020 Nov 10 |
1 |
| 25 |
30528247 | Corrigendum to "Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway" [J. Neuroimmunol. 299 (2016) 164-171]. | 2019 Jan 15 |
1 |
| 26 |
30682771 | mTOR Inhibitors in Advanced Biliary Tract Cancers. | 2019 Jan 24 |
1 |
| 27 |
30712550 | Duplicate - Corrigendum to "Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway" [J. Neuroimmunol. 299 (2016) 164-171]. | 2019 Feb 15 |
1 |
| 28 |
30796356 | mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition. | 2019 Aug |
1 |
| 29 |
31030237 | Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. | 2019 Sep |
1 |
| 30 |
31116586 | Everolimus induces G1 cell cycle arrest through autophagy-mediated protein degradation of cyclin D1 in breast cancer cells. | 2019 Aug 1 |
3 |
| 31 |
31465093 | Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. | 2019 Nov 1 |
1 |
| 32 |
29121714 | Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy. | 2018 Jul |
1 |
| 33 |
29251327 | Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. | 2018 Feb |
5 |
| 34 |
29428724 | Dual inhibition of mTORC1 and mTORC2 perturbs cytoskeletal organization and impairs endothelial cell elongation. | 2018 Feb 26 |
1 |
| 35 |
29507656 | Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. | 2018 Feb 6 |
1 |
| 36 |
29557694 | Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? | 2018 Apr |
1 |
| 37 |
29720580 | Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC). | 2018 May 3 |
2 |
| 38 |
29880014 | Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. | 2018 Jun 8 |
1 |
| 39 |
29895527 | The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. | 2018 Oct |
1 |
| 40 |
30104176 | A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. | 2018 Oct |
1 |
| 41 |
30160042 | Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways. | 2018 Oct |
2 |
| 42 |
30297804 | MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells. | 2018 Dec |
1 |
| 43 |
30410117 | A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells. | 2018 Nov 8 |
1 |
| 44 |
30456298 | mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. | 2018 |
1 |
| 45 |
27513674 | Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. | 2017 |
1 |
| 46 |
27935857 | Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. | 2017 Jan 10 |
1 |
| 47 |
28211162 | Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. | 2017 May |
2 |
| 48 |
28270607 | mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy. | 2017 Mar 21 |
1 |
| 49 |
28544747 | K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. | 2017 Sep |
1 |
| 50 |
28658205 | mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. | 2017 Jul 6 |
1 |